Age at onset of schizophrenia and neuroleptic dosage

被引:6
作者
Dernovsek, MZ [1 ]
Tavcar, R [1 ]
机构
[1] Univ Ljubljana, Hosp Psychiat, SI-1260 Ljubljana, Slovenia
关键词
D O I
10.1007/s001270050184
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Lower age at onset of schizophrenia has been traditionally associated with poorer response to treatment and less favourable prognosis. The aim of the study was to find out whether age at onset of schizophrenia is related to the dosage of typical neuroleptics in outpatients. Method: Age at onset was defined as age at first seeking of psychiatric help. Demographic, social and disease-related characteristics were studied in a group of 200 stable outpatients with schizophrenia (100 males and 100 females). Psychopathological symptoms were assessed with the Krawiecka Scale. Neuroleptic dosage was converted to milligrams of chlorpromazine equivalents and logarithmically transformed to obtain normal distribution. Results: Onset of schizophrenia occurred earlier in males than in females. The average dosage was 251.7 (SD 303.9) mg chlorpromazine equivalents. In a multivariate linear regression model, lower age at onset and higher sum of symptoms were related to the drug dosage. Conclusion: The results confirm the findings of other authors that patients with lower age at onset are less responsive to typical neuroleptics. Some of the patients with early onset would be more appropriately treated with atypical neuroleptics, which may have better therapeutic efficacy.
引用
收藏
页码:622 / 626
页数:5
相关论文
共 55 条
[41]   METHODOLOGICAL ASPECTS OF ONSET ASSESSMENT IN SCHIZOPHRENIA [J].
MAURER, K ;
HAFNER, H .
SCHIZOPHRENIA RESEARCH, 1995, 15 (03) :265-276
[42]  
Meltzer HY, 1997, AM J PSYCHIAT, V154, P475
[43]   CAG REPEAT EXPANSIONS AND SCHIZOPHRENIA - ASSOCIATION WITH DISEASE IN FEMALES AND WITH EARLY AGE-AT-ONSET [J].
MORRIS, AG ;
GAITONDE, E ;
MCKENNA, PJ ;
MOLLON, JD ;
HUNT, DM .
HUMAN MOLECULAR GENETICS, 1995, 4 (10) :1957-1961
[44]   RISK OF SCHIZOPHRENIA IN ADULTS BORN AFTER OBSTETRIC COMPLICATIONS AND THEIR ASSOCIATION WITH EARLY ONSET OF ILLNESS - A CONTROLLED-STUDY [J].
OCALLAGHAN, E ;
GIBSON, T ;
COLOHAN, HA ;
BUCKLEY, P ;
WALSHE, DG ;
LARKIN, C ;
WADDINGTON, JL .
BRITISH MEDICAL JOURNAL, 1992, 305 (6864) :1256-1259
[45]   RISPERIDONE IN THE TREATMENT OF PATIENTS WITH CHRONIC-SCHIZOPHRENIA - A MULTI-NATIONAL, MULTICENTER, DOUBLE-BLIND, PARALLEL-GROUP STUDY VERSUS HALOPERIDOL [J].
PEUSKENS, J .
BRITISH JOURNAL OF PSYCHIATRY, 1995, 166 :712-726
[46]   What do we really know about late-onset schizophrenia? [J].
RiecherRossler, A ;
Loffler, W ;
MunkJorgensen, P .
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 1997, 247 (04) :195-208
[47]   DO ORIENTAL PSYCHIATRIC-PATIENTS RECEIVE DIFFERENT DOSAGES OF PSYCHOTROPIC MEDICATION WHEN COMPARED WITH OCCIDENTALS [J].
ROSENBLAT, R ;
TANG, SW .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1987, 32 (04) :270-274
[48]   1ST-CONTACT RATE FOR SCHIZOPHRENIA IN COMMUNITY PSYCHIATRIC-CARE - CONSIDERATION OF THE ESTROGEN HYPOTHESIS [J].
SALOKANGAS, RKR .
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 1993, 242 (06) :337-346
[49]   GENDER AND THE USE OF NEUROLEPTICS IN SCHIZOPHRENIA FURTHER TESTING OF THE ESTROGEN HYPOTHESIS [J].
SALOKANGAS, RKR .
SCHIZOPHRENIA RESEARCH, 1995, 16 (01) :7-16
[50]  
Sandyk R, 1991, Funct Neurol, V6, P151